Serbia vs Singapore: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Serbia
91.0%
in 2025
Singapore
91.0%
in 2025
Serbia rank
61st
Singapore rank
61st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Serbia
- Singapore
How they compare
Serbia currently reports 91.0% against 91.0% in Singapore, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Singapore ahead.
Serbia ranks 61st and Singapore ranks 61st of 194 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Serbia | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 8.5% | 8.5% | Singapore |
| 2010s | 15.9% | 64.6% | 48.7% | Singapore |
| 2020s | 87.5% | 90.0% | 2.5% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Serbia or Singapore?
- Serbia, at 91.0% against 91.0% in Singapore as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Serbia and Singapore?
- 0.0%, with Serbia ahead.
- How many years of comparable data are there for Serbia and Singapore?
- 18 years are reported by both, from 2008 to 2025.
- How do Serbia and Singapore rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Serbia ranks 61st and Singapore ranks 61st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.